Research Article

You have full text access to this OnlineOpen article

Effects of a novel tylophorine analog on collagen-induced arthritis through inhibition of the innate immune response

  1. Xin You1,†,‖,
  2. Meng Pan1,‡,‖,
  3. Wenli Gao1,
  4. Her-Shyong Shiah1,
  5. Jian Tao1,
  6. Dongqing Zhang1,§,
  7. Fotios Koumpouras1,
  8. Shuang Wang1,¶,
  9. Hongyu Zhao1,
  10. Joseph A. Madri1,
  11. David Baker2,
  12. Yung-Chi Cheng1,
  13. Zhinan Yin1,*

Article first published online: 28 FEB 2006

DOI: 10.1002/art.21640

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 54, Issue 3, pages 877–886, March 2006

Additional Information

How to Cite

You, X., Pan, M., Gao, W., Shiah, H.-S., Tao, J., Zhang, D., Koumpouras, F., Wang, S., Zhao, H., Madri, J. A., Baker, D., Cheng, Y.-C. and Yin, Z. (2006), Effects of a novel tylophorine analog on collagen-induced arthritis through inhibition of the innate immune response. Arthritis & Rheumatism, 54: 877–886. doi: 10.1002/art.21640

Author Information

  1. 1

    Yale University, New Haven, Connecticut

  2. 2

    University of Tennessee, Knoxville

  1. †

    University of California, San Diego

  2. ‡

    Ruijing Hospital, Shanghai Second Medical University, Shanghai, China

  3. §

    Shanghai Jiao Torg University, Shanghai, China

  4. Columbia University, New York, New York

  1. ‖

    Drs. You and Pan contributed equally to this work.

*Section of Rheumatology, Yale University School of Medicine, Box 208031, The Anylan Center (TAC), Room 517, 300 Cedar Street, New Haven, CT 06520-8031

Publication History

  1. Issue published online: 28 FEB 2006
  2. Article first published online: 28 FEB 2006
  3. Manuscript Accepted: 10 NOV 2005
  4. Manuscript Received: 3 AUG 2005

Funded by

  • Arthritis Foundation Investigator award
  • NIH. Grant Numbers: K01-AR-02188, 1-R01-AI-056219

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (230K)

REFERENCES

  • 1
    Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996; 85: 307–10.
  • 2
    Aho K, Koskenvuo M, Tuominen J, Kaprio J. Occurrence of rheumatoid arthritis in a nationwide series of twins. J Rheumatol 1986; 13: 899–902.
  • 3
    Feldmann M, Maini RN, Bondeson J, Taylor P, Foxwell BM, Brennan FM. Cytokine blockade in rheumatoid arthritis. Adv Exp Med Biol 2001; 490: 119–27.
  • 4
    Keystone EC, Kavanaugh A. What to do with TNF failures. Expert Opin Drug Saf 2005; 4: 149–55.
  • 5
    Zink A, Listing J, Kary S, Ramlau P, Stoyanova-Scholz M, Babinsky K, et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 2005; 64: 1274–9.
  • 6
    Yin Z, Siegert S, Neure L, Grolms M, Liu L, Eggens U, et al. The elevated ratio of interferon γ/interleukin-4-positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin-4 but not by interleukin-10 or transforming growth factor β. Rheumatology (Oxford) 1999; 38: 1058–67.
  • 7
    Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen an experimental model of arthritis. J Exp Med 1977; 146: 857–68.
  • 8
    Luross JA, Williams NA. The genetic and immunopathological processes underlying collagen-induced arthritis. Immunology 2001; 103: 407–16.
    Direct Link:
  • 9
    Svensson L, Jirholt J, Holmdahl R, Jansson L. B cell-deficient mice do not develop type II collagen-induced arthritis (CIA). Clin Exp Immunol 1998; 111: 521–6.
    Direct Link:
  • 10
    Yoshino S, Cleland LG, Mayrhofer G. Treatment of collagen-induced arthritis in rats with a monoclonal antibody against the α/β T cell antigen receptor. Arthritis Rheum 1991; 34: 1039–47.
    Direct Link:
  • 11
    Mauri C, Williams RO, Walmsley M, Feldmann M. Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur J Immunol 1996; 26: 1511–8.
    Direct Link:
  • 12
    Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002; 2: 364–71.
  • 13
    Gao W, Lam W, Zhong S, Kaczmarek C, Baker DC, Cheng YC. Novel mode of action of tylophorine analogs as antitumor compounds. Cancer Res 2004; 64: 678–88.
  • 14
    Pan M, Kang I, Craft J, Yin Z. Resistance to development of collagen-induced arthritis in C57BL/6 mice is due to a defect in secondary, but not in primary, immune response. J Clin Immunol 2004; 24: 481–91.
  • 15
    Wang Y, Kristan J, Hao L, Lenkoski CS, Shen Y, Matis LA. A role for complement in antibody-mediated inflammation: C5-deficient DBA/1 mice are resistant to collagen-induced arthritis. J Immunol 2000; 164: 4340–7.
  • 16
    Kang I, Lee WW, Lee Y. Modulation of collagen-induced arthritis by IL-4 and dexamethasone: the synergistic effect of IL-4 and dexamethasone on the resolution of CIA. Immunopharmacology 2000; 49: 317–24.
  • 17
    Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999; 223: 77–92.
  • 18
    Johnson CR, Kitz D, Little JR. A method for the derivation and continuous propagation of cloned murine bone marrow macrophages. J Immunol Methods 1983; 65: 319–32.
  • 19
    Yin Z, Zhang DH, Welte T, Bahtiyar G, Jung S, Liu L, et al. Dominance of IL-12 over IL-4 in γ delta T cell differentiation leads to default production of IFN-γ: failure to down-regulate IL-12 receptor β2-chain expression. J Immunol 2000; 164: 3056–64.
  • 20
    Welte T, Zhang SS, Wang T, Zhang Z, Hesslein DG, Yin Z, et al. STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc Natl Acad Sci U S A 2003; 100: 1879–84.
  • 21
    Abramson SB, Amin A. Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology (Oxford) 2002; 41: 972–80.
  • 22
    Dayer JM. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology (Oxford) 2003; 42 Suppl 2: ii3–10.
  • 23
    Joosten LA, Helsen MM, Saxne T, van de Loo FA, Heinegard D, van Den Berg WB. IL-1α β blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-α blockade only ameliorates joint inflammation. J Immunol 1999; 163: 5049–55.
  • 24
    Tak PP, Gerlag DM, Aupperle KR, van de Geest DA, Overbeek M, Bennet BL, et al. Inhibitor of nuclear factor κB kinase β is a key regulator of synovial inflammation. Arthritis Rheum 2001; 44: 1897–907.
    Direct Link:
  • 25
    Seetharaman R, Mora AL, Nabozny G, Boothby M, Chen J. Essential role of T cell NF-κB activation in collagen-induced arthritis. J Immunol 1999; 163: 1577–83.
  • 26
    Van 't Hof RJ, Armour KJ, Smith LM, Armour KE, Wei XQ, Liew FY, et al. Requirement of the inducible nitric oxide synthase pathway for IL-1-induced osteoclastic bone resorption. Proc Natl Acad Sci U S A 2000; 97: 7993–8.
  • 27
    Ochi T, Ohkubo Y, Mutoh S. Role of cyclooxygenase-2, but not cyclooxygenase-1, on type II collagen-induced arthritis in DBA/1J mice. Biochem Pharmacol 2003; 66: 1055–60.
  • 28
    Han Z, Boyle DL, Manning AM, Firestein GS. AP-1 and NF-κB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 1998; 28: 197–208.
  • 29
    Miagkov AV, Kovalenko DV, Brown CE, Didsbury JR, Cogswell JP, Stimpson SA, et al. NF-κB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci U S A 1998; 95: 13859–64.
View Full Article (HTML) Get PDF (230K)